基于纳米材料的生物传感器用于阿尔茨海默病诊断的最新进展:一篇综述
Qing Liu1, Xuan Xu2, Tingting Zheng1
1Shanghai Key Laboratory of Green Chemistry and Chemical Processes, School of Chemistry and Molecular Engineering, East China Normal University, Dongchuan Road 500, Shanghai, 200241, P. R. China. ttzheng@chem.ecnu.edu.cn.
概括
早期阿尔茨海默病 (AD) 诊断正在使用纳米生物传感器取得进展. 这些敏感的工具在血液中检测到关键的AD生物标志物,为广泛查提供了传统测试的不那么侵入性的替代方案.
科学领域:
- 神经科学和生物医学工程
- 纳米材料和生物传感技术
背景情况:
- 阿尔茨海默氏症 (AD) 是一种主要的神经退行性疾病,其特征是β-粉样蛋白 (Aβ) 沉积,高酸化,突触干扰和神经炎症.
- 目前的诊断方法通常依赖于侵入性脑脊液 (CSF) 分析,限制了大规模的早期查.
- 新兴的非侵入性基于血液的生物标志物对于可访问的AD检测至关重要.
研究的目的:
- 审查用于检测阿尔茨海默病生物标志物的纳米生物传感器技术的最新进展.
- 突出纳米材料在提高AD诊断工具的敏感性和特异性的作用.
- 探索非侵入性生物传感用于早期AD诊断和查的潜力.
主要方法:
- 对纳米生物传感器用于阿尔茨海默病生物标志物检测的当前文献进行系统审查.
- 专注于基于电化学,光学和表面增强拉曼散射 (SERS) 的纳米生物传感器平台.
- 纳米材料应用在提高生物标志物检测灵敏度和特异性的分析.
主要成果:
- 基于纳米材料的生物传感器在检测关键的AD生物标志物,包括Aβ,tau蛋白和microRNA时,具有很高的灵敏度和特异性.
- 电化学,光学和SERS传感器显示出对准确和快速的AD生物标志物定量有显著的希望.
- 这些纳米生物传感器为早期AD检测提供了侵入性CSF测试的可行替代方案.
结论:
- 纳米生物传感器技术代表了对阿尔茨海默病敏感,特异性和非侵入性诊断工具的开发的重大突破.
- 将纳米材料集成到生物传感器中提高了它们的性能,为广泛的早期AD查铺平了道路.
- 在该领域进行进一步的研究和开发对于临床转化和改善患者治疗结果至关重要.
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261


